Bayer has joined the throng of drugmakers developing KRAS-targeting therapies for cancer by licensing an early-stage candidate from Kumquat Biosciences. The deal – which has a total value of up to ...

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway. The first patient has already been treated with bemdaneprocel, a ...

Heading into the second half of their 2025 financial year, Bayer leaders echo positive comments surrounding the company’s crop science division. What has them bullish? First, Bayer is optimistic the ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...